factuality_value
stringclasses
7 values
predicat@xml:space
stringclasses
1 value
predicat@charOffset
stringlengths
3
9
predicat@headOffset
stringlengths
3
9
predicat@id
stringclasses
206 values
predicat@text
stringlengths
2
124
predicat@type
stringclasses
29 values
predicat@charOffsetMin
int64
0
3.96k
predicat@charOffsetMax
int64
6
3.97k
subject@xml:space
stringclasses
1 value
subject@charOffset
stringlengths
3
9
subject@headOffset
stringlengths
3
9
subject@id
stringclasses
197 values
subject@text
stringlengths
2
49
subject@type
stringclasses
72 values
subject@charOffsetMin
int64
0
3.98k
subject@charOffsetMax
int64
3
4k
object@xml:space
stringclasses
1 value
object@charOffset
stringlengths
3
9
object@headOffset
stringlengths
3
9
object@id
stringclasses
198 values
object@text
stringlengths
2
53
object@type
stringclasses
73 values
object@charOffsetMin
int64
0
3.93k
object@charOffsetMax
int64
4
3.94k
id
stringclasses
58 values
raw_sent_text
stringlengths
20
749
sent_charOffset
stringlengths
4
9
sent_charOffsetMin
int64
0
3.88k
sent_charOffsetMax
int64
26
4.2k
formated_sentence
stringlengths
34
768
Probable
preserve
1703-1705
1703-1705
T95
in
TREATS
1,703
1,705
preserve
1635-1644
1635-1644
T90
ergometry
HealthCareActivity
1,635
1,644
preserve
1720-1722
1720-1722
T94
BP
Finding
1,720
1,722
A2
This study indicates that cycle ergometry at 50 and 75% of VO2 Peak elicit similar reductions in post exercise BP.
1603-1723
1,603
1,723
This study indicates that cycle @SUBJECT$ at 50 and 75% of VO2 Peak elicit similar reductions @PREDICAT$ post exercise @OBJECT$ .
Fact
preserve
2938-2952
2944-2952
T163
obese patients
PROCESS_OF
2,938
2,952
preserve
2938-2943
2938-2943
T160
obese
DiseaseOrSyndrome
2,938
2,943
preserve
2944-2952
2944-2952
T161
patients
PatientOrDisabledGroup
2,944
2,952
A1
Future studies should incorporate assessment of patient perceived satisfaction with weight loss, health status and quality-of-life evaluations and pharmacoeconomic data to aid clinicians in the decision-making process in terms of weight management of their obese patients.
2662-2953
2,662
2,953
Future studies should incorporate assessment of patient perceived satisfaction with weight loss, health status and quality-of-life evaluations and pharmacoeconomic data to aid clinicians in the decision-making process in terms of weight management of their @SUBJECT$ @PREDICAT$ @OBJECT$ .
Fact
preserve
1836-1849
1842-1849
T101
obese patient
PROCESS_OF
1,836
1,849
preserve
1836-1841
1836-1841
T98
obese
DiseaseOrSyndrome
1,836
1,841
preserve
1842-1849
1842-1849
T99
patient
PatientOrDisabledGroup
1,842
1,849
A2
Surgical intervention is reserved for the clinically severe obese patient [body mass index (BMI) > 40 kg/m2].
1770-1885
1,770
1,885
Surgical intervention is reserved for the clinically severe @SUBJECT$ @PREDICAT$ @OBJECT$ [body mass index (BMI) > 40 kg/m2].
Fact
preserve
1338-1352
1344-1352
T74
obese patients
PROCESS_OF
1,338
1,352
preserve
1338-1343
1338-1343
T70
obese
DiseaseOrSyndrome
1,338
1,343
preserve
1344-1352
1344-1352
T71
patients
PatientOrDisabledGroup
1,344
1,352
A4
There are no long term prospective studies that have demonstrated that weight reduction in obese patients improves survival.
1240-1371
1,240
1,371
There are no long term prospective studies that have demonstrated that weight reduction in @SUBJECT$ @PREDICAT$ @OBJECT$ improves survival.
Fact
preserve
1558-1578
1570-1578
T86
obese patients
PROCESS_OF
1,558
1,578
preserve
1558-1563
1558-1563
T82
obese
DiseaseOrSyndrome
1,558
1,563
preserve
1570-1578
1570-1578
T83
patients
PatientOrDisabledGroup
1,570
1,578
A5
However, on the basis of epidemiological data using the prevalence of disease and associated body mass index, it is generally accepted that weight reduction of 5 to 10% in obese patients is associated with significant health benefits.
1372-1626
1,372
1,626
However, on the basis of epidemiological data using the prevalence of disease and associated body mass index, it is generally accepted that weight reduction of 5 to 10% in @SUBJECT$ @PREDICAT$ @OBJECT$ is associated with significant health benefits.
Fact
preserve
1555-1557
1555-1557
T87
in
PROCESS_OF
1,555
1,557
preserve
1526-1542
1533-1542
T81
weight reduction
Finding
1,526
1,542
preserve
1570-1578
1570-1578
T83
patients
PatientOrDisabledGroup
1,570
1,578
A10
However, on the basis of epidemiological data using the prevalence of disease and associated body mass index, it is generally accepted that weight reduction of 5 to 10% in obese patients is associated with significant health benefits.
1372-1626
1,372
1,626
However, on the basis of epidemiological data using the prevalence of disease and associated body mass index, it is generally accepted that @SUBJECT$ of 5 to 10% @PREDICAT$ obese @OBJECT$ is associated with significant health benefits.
Fact
preserve
51-54
51-54
T5
for
TREATS
51
54
preserve
32-50
41-50
T3
surgical treatment
TherapeuticOrPreventiveProcedure
32
50
preserve
55-62
55-62
T4
obesity
DiseaseOrSyndrome
55
62
A11
Outcomes of pharmacological and surgical treatment for obesity.
0-63
0
63
Outcomes of pharmacological and @SUBJECT$ @PREDICAT$ @OBJECT$ .
Fact
preserve
699-706
699-706
T41
affects
AFFECTS
699
706
preserve
691-698
691-698
T39
Obesity
DiseaseOrSyndrome
691
698
preserve
718-724
718-724
T40
adults
AgeGroup
718
724
A13
Obesity affects 65 million adults in the US.
691-735
691
735
@SUBJECT$ @PREDICAT$ 65 million @OBJECT$ in the US.
Fact
preserve
1335-1337
1335-1337
T75
in
PROCESS_OF
1,335
1,337
preserve
1318-1334
1325-1334
T69
weight reduction
Finding
1,318
1,334
preserve
1344-1352
1344-1352
T71
patients
PatientOrDisabledGroup
1,344
1,352
A14
There are no long term prospective studies that have demonstrated that weight reduction in obese patients improves survival.
1240-1371
1,240
1,371
There are no long term prospective studies that have demonstrated that @SUBJECT$ @PREDICAT$ obese @OBJECT$ improves survival.
Probable
preserve
673-679
673-679
T45
relief
TREATS
673
679
preserve
639-646
639-646
T36
surgery
TherapeuticOrPreventiveProcedure
639
646
preserve
665-672
665-672
T38
symptom
SignOrSymptom
665
672
A3
Interim results from multicenter trials comparing coronary surgery and coronary angioplasty for the treatment of multivessel coronary disease suggest that coronary surgery may be better for symptom relief in angina, with fewer hospital admissions and therapeutic interventions.
463-758
463
758
Interim results from multicenter trials comparing coronary surgery and coronary angioplasty for the treatment of multivessel coronary disease suggest that coronary @SUBJECT$ may be better for @OBJECT$ @PREDICAT$ in angina, with fewer hospital admissions and therapeutic interventions.
Fact
preserve
795-809
802-809
T55
vessel disease
LOCATION_OF
795
809
preserve
795-801
795-801
T48
vessel
BodyPartOrganOrOrganComponent
795
801
preserve
802-809
802-809
T49
disease
DiseaseOrSyndrome
802
809
A4
Surgery for single- or double-vessel disease is appropriate when initial attempts at revascularization by coronary angioplasty have failed.
759-910
759
910
Surgery for single- or double- @SUBJECT$ @PREDICAT$ @OBJECT$ is appropriate when initial attempts at revascularization by coronary angioplasty have failed.
Possible
preserve
1397-1404
1397-1404
T93
benefit
TREATS
1,397
1,404
preserve
1415-1443
1426-1443
T91
myocardial revascularization
TherapeuticOrPreventiveProcedure
1,415
1,443
preserve
1384-1392
1384-1392
T89
patients
PatientOrDisabledGroup
1,384
1,392
A5
Recent studies of myocardial viability have examined the use of positron-emission tomography scanning to determine which patients may benefit most from myocardial revascularization.
1251-1444
1,251
1,444
Recent studies of myocardial viability have examined the use of positron-emission tomography scanning to determine which @OBJECT$ may @PREDICAT$ most from @SUBJECT$ .
Fact
preserve
162-166
162-166
T21
with
PROCESS_OF
162
166
preserve
167-183
176-183
T10
coronary disease
DiseaseOrSyndrome
167
183
preserve
154-161
154-161
T9
elderly
AgeGroup
154
161
A6
Coronary surgery remains an important therapeutic option for coronary revascularization, particularly in the elderly with coronary disease, in whom recent studies have demonstrated improvement of quality of life and long-term survival compared with medical treatment.
39-324
39
324
Coronary surgery remains an important therapeutic option for coronary revascularization, particularly in the @OBJECT$ @PREDICAT$ @SUBJECT$ , in whom recent studies have demonstrated improvement of quality of life and long-term survival compared with medical treatment.
Fact
preserve
96-99
96-99
T19
for
METHOD_OF
96
99
preserve
48-55
48-55
T5
surgery
TherapeuticOrPreventiveProcedure
48
55
preserve
100-132
115-132
T8
coronary revascularization
TherapeuticOrPreventiveProcedure
100
132
A10
Coronary surgery remains an important therapeutic option for coronary revascularization, particularly in the elderly with coronary disease, in whom recent studies have demonstrated improvement of quality of life and long-term survival compared with medical treatment.
39-324
39
324
Coronary @SUBJECT$ remains an important therapeutic option @PREDICAT$ @OBJECT$ , particularly in the elderly with coronary disease, in whom recent studies have demonstrated improvement of quality of life and long-term survival compared with medical treatment.
Fact
preserve
969-978
969-978
T71
treatment
TREATS
969
978
preserve
920-927
920-927
T58
surgery
TherapeuticOrPreventiveProcedure
920
927
preserve
982-999
994-999
T62
cardiogenic shock
PathologicFunction
982
999
A11
Coronary surgery may be a therapeutic option in the treatment of cardiogenic shock, particularly in the presence of three-vessel disease or the presence of complex lesions not amenable to angioplasty.
911-1129
911
1,129
Coronary @SUBJECT$ may be a therapeutic option in the @PREDICAT$ of @OBJECT$ , particularly in the presence of three-vessel disease or the presence of complex lesions not amenable to angioplasty.
Fact
preserve
1045-1059
1052-1059
T73
vessel disease
LOCATION_OF
1,045
1,059
preserve
1045-1051
1045-1051
T64
vessel
BodyPartOrganOrOrganComponent
1,045
1,051
preserve
1052-1059
1052-1059
T65
disease
DiseaseOrSyndrome
1,052
1,059
A12
Coronary surgery may be a therapeutic option in the treatment of cardiogenic shock, particularly in the presence of three-vessel disease or the presence of complex lesions not amenable to angioplasty.
911-1129
911
1,129
Coronary surgery may be a therapeutic option in the treatment of cardiogenic shock, particularly in the presence of three- @SUBJECT$ @PREDICAT$ @OBJECT$ or the presence of complex lesions not amenable to angioplasty.
Fact
preserve
874-876
874-876
T56
by
METHOD_OF
874
876
preserve
877-897
886-897
T54
coronary angioplasty
TherapeuticOrPreventiveProcedure
877
897
preserve
850-867
850-867
T53
revascularization
TherapeuticOrPreventiveProcedure
850
867
A15
Surgery for single- or double-vessel disease is appropriate when initial attempts at revascularization by coronary angioplasty have failed.
759-910
759
910
Surgery for single- or double-vessel disease is appropriate when initial attempts at @OBJECT$ @PREDICAT$ @SUBJECT$ have failed.
Fact
preserve
503-512
503-512
T42
comparing
compared_with
503
512
preserve
522-529
522-529
T31
surgery
TherapeuticOrPreventiveProcedure
522
529
preserve
540-560
549-560
T32
coronary angioplasty
TherapeuticOrPreventiveProcedure
540
560
A16
Interim results from multicenter trials comparing coronary surgery and coronary angioplasty for the treatment of multivessel coronary disease suggest that coronary surgery may be better for symptom relief in angina, with fewer hospital admissions and therapeutic interventions.
463-758
463
758
Interim results from multicenter trials @PREDICAT$ coronary @SUBJECT$ and @OBJECT$ for the treatment of multivessel coronary disease suggest that coronary surgery may be better for symptom relief in angina, with fewer hospital admissions and therapeutic interventions.
Fact
preserve
1321-1358
1350-1358
T92
positron-emission tomography scanning
ISA
1,321
1,358
preserve
1321-1349
1339-1349
T87
positron-emission tomography
DiagnosticProcedure
1,321
1,349
preserve
1350-1358
1350-1358
T88
scanning
DiagnosticProcedure
1,350
1,358
A17
Recent studies of myocardial viability have examined the use of positron-emission tomography scanning to determine which patients may benefit most from myocardial revascularization.
1251-1444
1,251
1,444
Recent studies of myocardial viability have examined the use of @SUBJECT$ @PREDICAT$ @OBJECT$ to determine which patients may benefit most from myocardial revascularization.
Fact
preserve
1424-1433
1424-1433
T83
decreased
INHIBITS
1,424
1,433
preserve
1418-1423
1418-1423
T72
ACE-I
PharmacologicSubstance
1,418
1,423
preserve
1459-1484
1477-1484
T75
brain natriuretic peptide
AminoAcidPeptideOrProtein
1,459
1,484
A1
Therapy with ACE-I decreased the levels of Ang II and brain natriuretic peptide and restored HGF production in response to heparin by 43+/-7-fold, comparable to the control response.
1399-1600
1,399
1,600
Therapy with @SUBJECT$ @PREDICAT$ the levels of Ang II and @OBJECT$ and restored HGF production in response to heparin by 43+/-7-fold, comparable to the control response.
Fact
preserve
1424-1433
1424-1433
T83
decreased
INHIBITS
1,424
1,433
preserve
1418-1423
1418-1423
T72
ACE-I
PharmacologicSubstance
1,418
1,423
preserve
1448-1454
1452-1454
T74
Ang II
AminoAcidPeptideOrProtein
1,448
1,454
A2
Therapy with ACE-I decreased the levels of Ang II and brain natriuretic peptide and restored HGF production in response to heparin by 43+/-7-fold, comparable to the control response.
1399-1600
1,399
1,600
Therapy with @SUBJECT$ @PREDICAT$ the levels of @OBJECT$ and brain natriuretic peptide and restored HGF production in response to heparin by 43+/-7-fold, comparable to the control response.
Fact
preserve
798-804
798-804
T42
caused
CAUSES
798
804
preserve
823-853
843-853
T39
anterior myocardial infarction
DiseaseOrSyndrome
823
853
preserve
773-797
790-797
T37
congestive heart failure
DiseaseOrSyndrome
773
797
A3
We studied 16 patients with congestive heart failure caused by previous anterior myocardial infarction in whom left ventricular ejection fraction was 35+/-8% (mean+/-SD).
745-927
745
927
We studied 16 patients with @OBJECT$ @PREDICAT$ by previous @SUBJECT$ in whom left ventricular ejection fraction was 35+/-8% (mean+/-SD).
Probable
preserve
1726-1737
1726-1737
T96
suppression
INHIBITS
1,726
1,737
preserve
1684-1689
1684-1689
T90
ACE-I
PharmacologicSubstance
1,684
1,689
preserve
1719-1725
1723-1725
T93
Ang II
AminoAcidPeptideOrProtein
1,719
1,725
A4
In conclusion, impaired HGF production was restored after the treatment with ACE-I probably by the mechanism of Ang II suppression.
1601-1738
1,601
1,738
In conclusion, impaired HGF production was restored after the treatment with @SUBJECT$ probably by the mechanism of @OBJECT$ @PREDICAT$ .
Fact
preserve
987-991
987-991
T55
with
USES
987
991
preserve
977-986
977-986
T45
treatment
TherapeuticOrPreventiveProcedure
977
986
preserve
992-997
992-997
T46
ACE-I
PharmacologicSubstance
992
997
A5
Before and approximately 4 weeks after the treatment with ACE-I, blood samples were collected to measure the levels of HGF, Ang II, and brain natriuretic peptide as a biochemical marker for severity of heart failure.
928-1163
928
1,163
Before and approximately 4 weeks after the @SUBJECT$ @PREDICAT$ @OBJECT$ , blood samples were collected to measure the levels of HGF, Ang II, and brain natriuretic peptide as a biochemical marker for severity of heart failure.
Fact
preserve
1285-1289
1285-1289
T70
with
PROCESS_OF
1,285
1,289
preserve
1290-1303
1296-1303
T64
heart failure
DiseaseOrSyndrome
1,290
1,303
preserve
1276-1284
1276-1284
T63
patients
PatientOrDisabledGroup
1,276
1,284
A6
However, in patients with heart failure, HGF response to heparin was significantly attenuated (24+/-5-fold, P<0.05 vs control).
1264-1398
1,264
1,398
However, in @OBJECT$ @PREDICAT$ @SUBJECT$ , HGF response to heparin was significantly attenuated (24+/-5-fold, P<0.05 vs control).
Fact
preserve
431-444
431-444
T23
downregulated
INHIBITS
431
444
preserve
448-462
448-459
T21
angiotensin II
AminoAcidPeptideOrProtein
448
462
preserve
413-416
413-416
T19
HGF
AminoAcidPeptideOrProtein
413
416
A7
HGF production is downregulated by angiotensin II (Ang II) in vitro.
413-487
413
487
@OBJECT$ production is @PREDICAT$ by @SUBJECT$ (Ang II) in vitro.
Possible
preserve
1816-1818
1816-1818
T104
in
TREATS
1,816
1,818
preserve
1767-1772
1767-1772
T99
ACE-I
PharmacologicSubstance
1,767
1,772
preserve
1819-1827
1819-1827
T101
patients
PatientOrDisabledGroup
1,819
1,827
A8
This novel effect of ACE-I may contribute to the clinical improvement in patients with heart failure and thereby may have an important therapeutic implication.
1739-1911
1,739
1,911
This novel effect of @SUBJECT$ may contribute to the clinical improvement @PREDICAT$ @OBJECT$ with heart failure and thereby may have an important therapeutic implication.
Fact
preserve
768-772
768-772
T41
with
PROCESS_OF
768
772
preserve
773-797
790-797
T37
congestive heart failure
DiseaseOrSyndrome
773
797
preserve
759-767
759-767
T36
patients
PatientOrDisabledGroup
759
767
A9
We studied 16 patients with congestive heart failure caused by previous anterior myocardial infarction in whom left ventricular ejection fraction was 35+/-8% (mean+/-SD).
745-927
745
927
We studied 16 @OBJECT$ @PREDICAT$ @SUBJECT$ caused by previous anterior myocardial infarction in whom left ventricular ejection fraction was 35+/-8% (mean+/-SD).
Fact
preserve
576-578
576-578
T35
in
TREATS
576
578
preserve
569-575
573-575
T28
Ang II
AminoAcidPeptideOrProtein
569
575
preserve
579-587
579-587
T29
patients
PatientOrDisabledGroup
579
587
A10
We hypothesized that HGF production is impaired as the result of increased Ang II in patients with congestive heart failure, and that if so, the impaired production should be restored with angiotensin-converting enzyme inhibitors (ACE-I).
488-744
488
744
We hypothesized that HGF production is impaired as the result of increased @SUBJECT$ @PREDICAT$ @OBJECT$ with congestive heart failure, and that if so, the impaired production should be restored with angiotensin-converting enzyme inhibitors (ACE-I).
Fact
preserve
194-198
194-198
T10
with
PROCESS_OF
194
198
preserve
199-230
223-230
T9
congestive heart failure
DiseaseOrSyndrome
199
230
preserve
185-193
185-193
T8
patients
PatientOrDisabledGroup
185
193
A11
Endothelium-dependent vasodilation is impaired in patients with congestive heart failure.
135-231
135
231
Endothelium-dependent vasodilation is impaired in @OBJECT$ @PREDICAT$ @SUBJECT$ .
Possible
preserve
1816-1818
1816-1818
T104
in
TREATS
1,816
1,818
preserve
1767-1772
1767-1772
T99
ACE-I
PharmacologicSubstance
1,767
1,772
preserve
1833-1852
1845-1852
T102
heart failure
DiseaseOrSyndrome
1,833
1,852
A12
This novel effect of ACE-I may contribute to the clinical improvement in patients with heart failure and thereby may have an important therapeutic implication.
1739-1911
1,739
1,911
This novel effect of @SUBJECT$ may contribute to the clinical improvement @PREDICAT$ patients with @OBJECT$ and thereby may have an important therapeutic implication.
Fact
preserve
1413-1417
1413-1417
T82
with
USES
1,413
1,417
preserve
1399-1406
1399-1406
T71
Therapy
TherapeuticOrPreventiveProcedure
1,399
1,406
preserve
1418-1423
1418-1423
T72
ACE-I
PharmacologicSubstance
1,418
1,423
A13
Therapy with ACE-I decreased the levels of Ang II and brain natriuretic peptide and restored HGF production in response to heparin by 43+/-7-fold, comparable to the control response.
1399-1600
1,399
1,600
@SUBJECT$ @PREDICAT$ @OBJECT$ decreased the levels of Ang II and brain natriuretic peptide and restored HGF production in response to heparin by 43+/-7-fold, comparable to the control response.
Fact
preserve
258-348
289-291
T18
hepatocyte growth factor (HGF) is one of the most potent and specific growth factors
ISA
258
348
preserve
258-282
276-282
T12
hepatocyte growth factor
AminoAcidPeptideOrProtein
258
282
preserve
334-348
341-348
T16
growth factors
BiologicallyActiveSubstance
334
348
A16
For vascular endothelium, hepatocyte growth factor (HGF) is one of the most potent and specific growth factors, which acts protectively against endothelial dysfunction.
232-412
232
412
For vascular endothelium, @SUBJECT$ @PREDICAT$ @OBJECT$ , which acts protectively against endothelial dysfunction.
Fact
preserve
1216-1225
1216-1225
T62
increased
STIMULATES
1,216
1,225
preserve
1208-1215
1208-1215
T58
heparin
BiologicallyActiveSubstance
1,208
1,215
preserve
1226-1229
1226-1229
T59
HGF
AminoAcidPeptideOrProtein
1,226
1,229
A17
We also studied 5 control subjects, in whom heparin increased HGF production to 48+/-5-fold.
1164-1263
1,164
1,263
We also studied 5 control subjects, in whom @SUBJECT$ @PREDICAT$ @OBJECT$ production to 48+/-5-fold.
Fact
preserve
1828-1832
1828-1832
T105
with
PROCESS_OF
1,828
1,832
preserve
1833-1852
1845-1852
T102
heart failure
DiseaseOrSyndrome
1,833
1,852
preserve
1819-1827
1819-1827
T101
patients
PatientOrDisabledGroup
1,819
1,827
A19
This novel effect of ACE-I may contribute to the clinical improvement in patients with heart failure and thereby may have an important therapeutic implication.
1739-1911
1,739
1,911
This novel effect of ACE-I may contribute to the clinical improvement in @OBJECT$ @PREDICAT$ @SUBJECT$ and thereby may have an important therapeutic implication.
Fact
preserve
1679-1683
1679-1683
T95
with
USES
1,679
1,683
preserve
1669-1678
1669-1678
T89
treatment
TherapeuticOrPreventiveProcedure
1,669
1,678
preserve
1684-1689
1684-1689
T90
ACE-I
PharmacologicSubstance
1,684
1,689
A20
In conclusion, impaired HGF production was restored after the treatment with ACE-I probably by the mechanism of Ang II suppression.
1601-1738
1,601
1,738
In conclusion, impaired HGF production was restored after the @SUBJECT$ @PREDICAT$ @OBJECT$ probably by the mechanism of Ang II suppression.
Fact
preserve
1670-1684
1678-1684
T86
elderly people
PROCESS_OF
1,670
1,684
preserve
1697-1716
1704-1716
T80
atrial fibrillation
PathologicFunction
1,697
1,716
preserve
1670-1677
1670-1677
T78
elderly
AgeGroup
1,670
1,677
A1
CONCLUSIONS: Most elderly people with atrial fibrillation would accept treatment to prevent stroke.
1652-1758
1,652
1,758
CONCLUSIONS: Most @OBJECT$ @PREDICAT$ with @SUBJECT$ would accept treatment to prevent stroke.
Fact
preserve
1065-1079
1073-1079
T55
elderly people
PROCESS_OF
1,065
1,079
preserve
1085-1104
1092-1104
T52
atrial fibrillation
PathologicFunction
1,085
1,104
preserve
1065-1072
1065-1072
T50
elderly
AgeGroup
1,065
1,072
A2
RESULTS: Two hundred and seven elderly people with atrial fibrillation were identified.
1034-1127
1,034
1,127
RESULTS: Two hundred and seven @OBJECT$ @PREDICAT$ with @SUBJECT$ were identified.
Fact
preserve
1204-1211
1204-1211
T64
prevent
PREVENTS
1,204
1,211
preserve
1185-1194
1185-1194
T58
treatment
TherapeuticOrPreventiveProcedure
1,185
1,194
preserve
1212-1218
1212-1218
T59
stroke
DiseaseOrSyndrome
1,212
1,218
A3
Almost all subjects expressed a willingness to undertake treatment to prevent stroke and preferred blood testing performed outside of hospital.
1128-1277
1,128
1,277
Almost all subjects expressed a willingness to undertake @SUBJECT$ to @PREDICAT$ @OBJECT$ and preferred blood testing performed outside of hospital.
Fact
preserve
410-414
410-414
T23
with
PROCESS_OF
410
414
preserve
415-434
422-434
T20
atrial fibrillation
PathologicFunction
415
434
preserve
402-409
402-409
T19
elderly
AgeGroup
402
409
A4
AIM: To investigate the prevalence of disability, cognitive impairment, and problems with compliance in a representative sample of the elderly with atrial fibrillation, and to determine whether they would want treatment and how they would like services to be arranged.
254-547
254
547
AIM: To investigate the prevalence of disability, cognitive impairment, and problems with compliance in a representative sample of the @OBJECT$ @PREDICAT$ @SUBJECT$ , and to determine whether they would want treatment and how they would like services to be arranged.
Fact
preserve
1685-1689
1685-1689
T84
with
PROCESS_OF
1,685
1,689
preserve
1697-1716
1704-1716
T80
atrial fibrillation
PathologicFunction
1,697
1,716
preserve
1678-1684
1678-1684
T79
people
PopulationGroup
1,678
1,684
A5
CONCLUSIONS: Most elderly people with atrial fibrillation would accept treatment to prevent stroke.
1652-1758
1,652
1,758
CONCLUSIONS: Most elderly @OBJECT$ @PREDICAT$ @SUBJECT$ would accept treatment to prevent stroke.
Fact
preserve
1080-1084
1080-1084
T54
with
PROCESS_OF
1,080
1,084
preserve
1085-1104
1092-1104
T52
atrial fibrillation
PathologicFunction
1,085
1,104
preserve
1073-1079
1073-1079
T51
people
PopulationGroup
1,073
1,079
A6
RESULTS: Two hundred and seven elderly people with atrial fibrillation were identified.
1034-1127
1,034
1,127
RESULTS: Two hundred and seven elderly @OBJECT$ @PREDICAT$ @SUBJECT$ were identified.
Fact
preserve
1065-1079
1073-1079
T53
elderly people
ISA
1,065
1,079
preserve
1065-1072
1065-1072
T50
elderly
AgeGroup
1,065
1,072
preserve
1073-1079
1073-1079
T51
people
PopulationGroup
1,073
1,079
A7
RESULTS: Two hundred and seven elderly people with atrial fibrillation were identified.
1034-1127
1,034
1,127
RESULTS: Two hundred and seven @SUBJECT$ @PREDICAT$ @OBJECT$ with atrial fibrillation were identified.
Fact
preserve
1743-1750
1743-1750
T85
prevent
PREVENTS
1,743
1,750
preserve
1730-1739
1730-1739
T81
treatment
TherapeuticOrPreventiveProcedure
1,730
1,739
preserve
1751-1757
1751-1757
T82
stroke
DiseaseOrSyndrome
1,751
1,757
A9
CONCLUSIONS: Most elderly people with atrial fibrillation would accept treatment to prevent stroke.
1652-1758
1,652
1,758
CONCLUSIONS: Most elderly people with atrial fibrillation would accept @SUBJECT$ to @PREDICAT$ @OBJECT$ .
Fact
preserve
31-35
31-35
T7
with
PROCESS_OF
31
35
preserve
36-55
43-55
T3
atrial fibrillation
PathologicFunction
36
55
preserve
22-30
22-30
T2
patients
PatientOrDisabledGroup
22
30
A10
A community survey of patients with atrial fibrillation: associated disabilities and treatment preferences.
0-114
0
114
A community survey of @OBJECT$ @PREDICAT$ @SUBJECT$ : associated disabilities and treatment preferences.
Fact
preserve
1670-1684
1678-1684
T83
elderly people
ISA
1,670
1,684
preserve
1670-1677
1670-1677
T78
elderly
AgeGroup
1,670
1,677
preserve
1678-1684
1678-1684
T79
people
PopulationGroup
1,678
1,684
A12
CONCLUSIONS: Most elderly people with atrial fibrillation would accept treatment to prevent stroke.
1652-1758
1,652
1,758
CONCLUSIONS: Most @SUBJECT$ @PREDICAT$ @OBJECT$ with atrial fibrillation would accept treatment to prevent stroke.
Fact
preserve
626-630
626-630
T31
with
PROCESS_OF
626
630
preserve
631-650
638-650
T29
atrial fibrillation
PathologicFunction
631
650
preserve
595-602
595-602
T27
elderly
AgeGroup
595
602
A13
METHOD: In a survey of a random sample of 4843 elderly subjects, those with atrial fibrillation were identified using electrocardiograms.
548-692
548
692
METHOD: In a survey of a random sample of 4843 @OBJECT$ subjects, those @PREDICAT$ @SUBJECT$ were identified using electrocardiograms.
Fact
preserve
1594-1605
1594-1605
T86
predisposes
PREDISPOSES
1,594
1,605
preserve
1571-1588
1580-1588
T83
motility disorder
PathologicFunction
1,571
1,588
preserve
1629-1638
1629-1638
T84
dysphagia
DiseaseOrSyndrome
1,629
1,638
A2
When performed prior to fundoplication, it appears to be of significant value in detecting a subtle functional motility disorder that predisposes to postoperative dysphagia.
1453-1639
1,453
1,639
When performed prior to fundoplication, it appears to be of significant value in detecting a subtle functional @SUBJECT$ that @PREDICAT$ to postoperative @OBJECT$ .
Fact
preserve
327-331
327-331
T21
have
PROCESS_OF
327
331
preserve
343-371
360-371
T19
esophageal dysmotility
DiseaseOrSyndrome
343
371
preserve
302-310
302-310
T16
patients
PatientOrDisabledGroup
302
310
A3
This is more likely in those patients with reflux who have concurrent esophageal dysmotility.
266-372
266
372
This is more likely in those @OBJECT$ with reflux who @PREDICAT$ concurrent @SUBJECT$ .
Counterfact
preserve
1245-1248
1245-1248
T75
had
PROCESS_OF
1,245
1,248
preserve
1252-1261
1252-1261
T68
dysphagia
DiseaseOrSyndrome
1,252
1,261
preserve
1232-1240
1232-1240
T67
patients
PatientOrDisabledGroup
1,232
1,240
A4
Of the 21 patients who had no dysphagia after surgery, 20 patients had normal preoperative jello esophageal transit, showing a specificity of 95%.
1222-1381
1,222
1,381
Of the 21 @OBJECT$ who @PREDICAT$ no @SUBJECT$ after surgery, 20 patients had normal preoperative jello esophageal transit, showing a specificity of 95%.
Fact
preserve
129-132
129-132
T12
for
TREATS
129
132
preserve
104-118
104-118
T6
Fundoplication
TherapeuticOrPreventiveProcedure
104
118
preserve
133-164
157-164
T7
gastroesophageal reflux disease
DiseaseOrSyndrome
133
164
A7
Fundoplication performed for gastroesophageal reflux disease may be complicated by postoperative dysphagia despite successful reduction in reflux symptoms.
104-265
104
265
@SUBJECT$ performed @PREDICAT$ @OBJECT$ may be complicated by postoperative dysphagia despite successful reduction in reflux symptoms.
Fact
preserve
311-315
311-315
T20
with
PROCESS_OF
311
315
preserve
316-322
316-322
T17
reflux
PathologicFunction
316
322
preserve
302-310
302-310
T16
patients
PatientOrDisabledGroup
302
310
A8
This is more likely in those patients with reflux who have concurrent esophageal dysmotility.
266-372
266
372
This is more likely in those @OBJECT$ @PREDICAT$ @SUBJECT$ who have concurrent esophageal dysmotility.
Fact
preserve
1085-1088
1085-1088
T65
had
PROCESS_OF
1,085
1,088
preserve
1089-1098
1089-1098
T58
dysphagia
DiseaseOrSyndrome
1,089
1,098
preserve
1076-1084
1076-1084
T57
patients
PatientOrDisabledGroup
1,076
1,084
A9
Six months after surgery, five patients had dysphagia and of these four were found to have abnormal preoperative jello esophageal transit, for a sensitivity of 80%.
1045-1221
1,045
1,221
Six months after surgery, five @OBJECT$ @PREDICAT$ @SUBJECT$ and of these four were found to have abnormal preoperative jello esophageal transit, for a sensitivity of 80%.
Fact
preserve
829-852
840-852
T48
intestinal side-effects
LOCATION_OF
829
852
preserve
829-839
829-839
T42
intestinal
BodyPartOrganOrOrganComponent
829
839
preserve
840-852
840-852
T43
side-effects
PathologicFunction
840
852
A1
Because of its mechanism of action, this drug can induce intestinal side-effects which tend to decrease with time and with the reduction of fat intake, thus improving diet compliance.
766-961
766
961
Because of its mechanism of action, this drug can induce @SUBJECT$ @PREDICAT$ @OBJECT$ which tend to decrease with time and with the reduction of fat intake, thus improving diet compliance.
Probable
preserve
822-828
822-828
T47
induce
CAUSES
822
828
preserve
807-811
807-811
T41
drug
PharmacologicSubstance
807
811
preserve
840-852
840-852
T43
side-effects
PathologicFunction
840
852
A4
Because of its mechanism of action, this drug can induce intestinal side-effects which tend to decrease with time and with the reduction of fat intake, thus improving diet compliance.
766-961
766
961
Because of its mechanism of action, this @SUBJECT$ can @PREDICAT$ intestinal @OBJECT$ which tend to decrease with time and with the reduction of fat intake, thus improving diet compliance.
Fact
preserve
1954-1958
1954-1958
T124
with
PROCESS_OF
1,954
1,958
preserve
1959-1993
1982-1993
T110
left ventricular enlargement
PathologicFunction
1,959
1,993
preserve
1945-1953
1945-1953
T109
Patients
PatientOrDisabledGroup
1,945
1,953
A1
Patients with left ventricular enlargement and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving aspirin therapy alone.
1945-2124
1,945
2,124
@OBJECT$ @PREDICAT$ @SUBJECT$ and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving aspirin therapy alone.
Fact
preserve
1909-1913
1909-1913
T108
with
PROCESS_OF
1,909
1,913
preserve
1926-1943
1935-1943
T107
cerebral ischemia
DiseaseOrSyndrome
1,926
1,943
preserve
1900-1908
1900-1908
T106
patients
PatientOrDisabledGroup
1,900
1,908
A2
CONCLUSION: Abnormalities are commonly found by TEE in patients with unexplained cerebral ischemia.
1839-1944
1,839
1,944
CONCLUSION: Abnormalities are commonly found by TEE in @OBJECT$ @PREDICAT$ unexplained @SUBJECT$ .
Probable
preserve
2194-2196
2194-2196
T134
in
TREATS
2,194
2,196
preserve
2161-2176
2161-2176
T130
anticoagulation
TherapeuticOrPreventiveProcedure
2,161
2,176
preserve
2211-2217
2211-2217
T132
stroke
DiseaseOrSyndrome
2,211
2,217
A3
Empiric therapy with systemic anticoagulation may be indicated in patients with stroke unexplained by carotid atherosclerotic disease.
2125-2271
2,125
2,271
Empiric therapy with systemic @SUBJECT$ may be indicated @PREDICAT$ patients with @OBJECT$ unexplained by carotid atherosclerotic disease.
Fact
preserve
1689-1698
1689-1698
T101
receiving
ADMINISTERED_TO
1,689
1,698
preserve
1699-1706
1699-1706
T92
aspirin
OrganicChemical
1,699
1,706
preserve
1680-1688
1680-1688
T91
patients
PatientOrDisabledGroup
1,680
1,688
A5
Among patients receiving aspirin, a higher recurrent stroke rate was noted in those with left ventricular enlargement and atherosclerotic aortic plaque.
1674-1838
1,674
1,838
Among @OBJECT$ @PREDICAT$ @SUBJECT$ , a higher recurrent stroke rate was noted in those with left ventricular enlargement and atherosclerotic aortic plaque.
Fact
preserve
2102-2117
2110-2117
T126
aspirin therapy
USES
2,102
2,117
preserve
2110-2117
2110-2117
T122
therapy
TherapeuticOrPreventiveProcedure
2,110
2,117
preserve
2102-2109
2102-2109
T121
aspirin
OrganicChemical
2,102
2,109
A6
Patients with left ventricular enlargement and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving aspirin therapy alone.
1945-2124
1,945
2,124
Patients with left ventricular enlargement and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving @OBJECT$ @PREDICAT$ @SUBJECT$ alone.
Fact
preserve
1755-1757
1755-1757
T102
in
COEXISTS_WITH
1,755
1,757
preserve
1733-1739
1733-1739
T95
stroke
DiseaseOrSyndrome
1,733
1,739
preserve
1808-1837
1831-1837
T100
atherosclerotic aortic plaque
AcquiredAbnormality
1,808
1,837
A7
Among patients receiving aspirin, a higher recurrent stroke rate was noted in those with left ventricular enlargement and atherosclerotic aortic plaque.
1674-1838
1,674
1,838
Among patients receiving aspirin, a higher recurrent @SUBJECT$ rate was noted @PREDICAT$ those with left ventricular enlargement and @OBJECT$ .
Fact
preserve
1325-1341
1334-1341
T71
warfarin therapy
ISA
1,325
1,341
preserve
1325-1333
1325-1333
T69
warfarin
HazardousOrPoisonousSubstance
1,325
1,333
preserve
1334-1341
1334-1341
T70
therapy
TherapeuticOrPreventiveProcedure
1,334
1,341
A8
RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the patients receiving warfarin therapy (P <.02).
1175-1351
1,175
1,351
RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the patients receiving @SUBJECT$ @PREDICAT$ @OBJECT$ (P <.02).
Fact
preserve
1325-1341
1334-1341
T74
warfarin therapy
ADMINISTERED_TO
1,325
1,341
preserve
1325-1333
1325-1333
T69
warfarin
HazardousOrPoisonousSubstance
1,325
1,333
preserve
1306-1314
1306-1314
T68
patients
PatientOrDisabledGroup
1,306
1,314
A10
RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the patients receiving warfarin therapy (P <.02).
1175-1351
1,175
1,351
RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the @OBJECT$ receiving @SUBJECT$ @PREDICAT$ (P <.02).
Fact
preserve
1325-1341
1334-1341
T73
warfarin therapy
USES
1,325
1,341
preserve
1334-1341
1334-1341
T70
therapy
TherapeuticOrPreventiveProcedure
1,334
1,341
preserve
1325-1333
1325-1333
T69
warfarin
HazardousOrPoisonousSubstance
1,325
1,333
A11
RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the patients receiving warfarin therapy (P <.02).
1175-1351
1,175
1,351
RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the patients receiving @OBJECT$ @PREDICAT$ @SUBJECT$ (P <.02).
Fact
preserve
2206-2210
2206-2210
T135
with
PROCESS_OF
2,206
2,210
preserve
2211-2217
2211-2217
T132
stroke
DiseaseOrSyndrome
2,211
2,217
preserve
2197-2205
2197-2205
T131
patients
PatientOrDisabledGroup
2,197
2,205
A13
Empiric therapy with systemic anticoagulation may be indicated in patients with stroke unexplained by carotid atherosclerotic disease.
2125-2271
2,125
2,271
Empiric therapy with systemic anticoagulation may be indicated in @OBJECT$ @PREDICAT$ @SUBJECT$ unexplained by carotid atherosclerotic disease.
Fact
preserve
1824-1837
1831-1837
T104
aortic plaque
LOCATION_OF
1,824
1,837
preserve
1824-1830
1824-1830
T99
aortic
BodyPartOrganOrOrganComponent
1,824
1,830
preserve
1808-1837
1831-1837
T100
atherosclerotic aortic plaque
AcquiredAbnormality
1,808
1,837
A14
Among patients receiving aspirin, a higher recurrent stroke rate was noted in those with left ventricular enlargement and atherosclerotic aortic plaque.
1674-1838
1,674
1,838
Among patients receiving aspirin, a higher recurrent stroke rate was noted in those with left ventricular enlargement and @OBJECT$ @SUBJECT$ @PREDICAT$ .
Fact
preserve
347-351
347-351
T16
with
PROCESS_OF
347
351
preserve
364-381
373-381
T15
cerebral ischemia
DiseaseOrSyndrome
364
381
preserve
338-346
338-346
T14
patients
PatientOrDisabledGroup
338
346
A15
BACKGROUND: Transesophageal echocardiography (TEE) continues to play a prominent role in the evaluation of patients with unexplained cerebral ischemia.
224-382
224
382
BACKGROUND: Transesophageal echocardiography (TEE) continues to play a prominent role in the evaluation of @OBJECT$ @PREDICAT$ unexplained @SUBJECT$ .
Fact
preserve
2102-2117
2110-2117
T123
aspirin therapy
ISA
2,102
2,117
preserve
2102-2109
2102-2109
T121
aspirin
OrganicChemical
2,102
2,109
preserve
2110-2117
2110-2117
T122
therapy
TherapeuticOrPreventiveProcedure
2,110
2,117
A16
Patients with left ventricular enlargement and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving aspirin therapy alone.
1945-2124
1,945
2,124
Patients with left ventricular enlargement and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving @SUBJECT$ @PREDICAT$ @OBJECT$ alone.
Fact
preserve
1755-1757
1755-1757
T102
in
COEXISTS_WITH
1,755
1,757
preserve
1733-1739
1733-1739
T95
stroke
DiseaseOrSyndrome
1,733
1,739
preserve
1769-1797
1786-1797
T98
left ventricular enlargement
PathologicFunction
1,769
1,797
A18
Among patients receiving aspirin, a higher recurrent stroke rate was noted in those with left ventricular enlargement and atherosclerotic aortic plaque.
1674-1838
1,674
1,838
Among patients receiving aspirin, a higher recurrent @SUBJECT$ rate was noted @PREDICAT$ those with @OBJECT$ and atherosclerotic aortic plaque.
Fact
preserve
1315-1324
1315-1324
T72
receiving
ADMINISTERED_TO
1,315
1,324
preserve
1334-1341
1334-1341
T70
therapy
TherapeuticOrPreventiveProcedure
1,334
1,341
preserve
1306-1314
1306-1314
T68
patients
PatientOrDisabledGroup
1,306
1,314
A19
RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the patients receiving warfarin therapy (P <.02).
1175-1351
1,175
1,351
RESULTS: Recurrent stroke occurred in 17 of 132 (13%) of the patients in the aspirin group versus 5 of 110 (5%) of the @OBJECT$ @PREDICAT$ warfarin @SUBJECT$ (P <.02).
Probable
preserve
2194-2196
2194-2196
T134
in
TREATS
2,194
2,196
preserve
2161-2176
2161-2176
T130
anticoagulation
TherapeuticOrPreventiveProcedure
2,161
2,176
preserve
2197-2205
2197-2205
T131
patients
PatientOrDisabledGroup
2,197
2,205
A20
Empiric therapy with systemic anticoagulation may be indicated in patients with stroke unexplained by carotid atherosclerotic disease.
2125-2271
2,125
2,271
Empiric therapy with systemic @SUBJECT$ may be indicated @PREDICAT$ @OBJECT$ with stroke unexplained by carotid atherosclerotic disease.
Fact
preserve
2011-2024
2018-2024
T125
aortic plaque
LOCATION_OF
2,011
2,024
preserve
2011-2017
2011-2017
T112
aortic
BodyPartOrganOrOrganComponent
2,011
2,017
preserve
2018-2024
2018-2024
T113
plaque
AcquiredAbnormality
2,018
2,024
A21
Patients with left ventricular enlargement and demonstrable aortic plaque on TEE study are at increased risk for recurrent stroke when receiving aspirin therapy alone.
1945-2124
1,945
2,124
Patients with left ventricular enlargement and demonstrable @SUBJECT$ @PREDICAT$ @OBJECT$ on TEE study are at increased risk for recurrent stroke when receiving aspirin therapy alone.
Fact
preserve
472-493
485-493
T30
hypertensive patients
PROCESS_OF
472
493
preserve
472-484
472-484
T28
hypertensive
Finding
472
484
preserve
485-493
485-493
T29
patients
PatientOrDisabledGroup
485
493
A1
3 days after discontinuing therapy in previously well-controlled mild to moderate hypertensive patients.
384-494
384
494
3 days after discontinuing therapy in previously well-controlled mild to moderate @SUBJECT$ @PREDICAT$ @OBJECT$ .
Uncommitted
preserve
419-421
419-421
T31
in
TREATS
419
421
preserve
411-418
411-418
T24
therapy
TherapeuticOrPreventiveProcedure
411
418
preserve
472-484
472-484
T28
hypertensive
Finding
472
484
A3
3 days after discontinuing therapy in previously well-controlled mild to moderate hypertensive patients.
384-494
384
494
3 days after discontinuing @SUBJECT$ @PREDICAT$ previously well-controlled mild to moderate @OBJECT$ patients.
Fact
preserve
224-233
224-233
T15
treatment
TREATS
224
233
preserve
116-134
124-134
T8
calcium antagonist
PharmacologicSubstance
116
134
preserve
237-249
237-249
T13
hypertension
DiseaseOrSyndrome
237
249
A4
Amlodipine is a calcium antagonist with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the treatment of hypertension.
100-250
100
250
Amlodipine is a @SUBJECT$ with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the @PREDICAT$ of @OBJECT$ .
Fact
preserve
100-134
124-134
T14
Amlodipine is a calcium antagonist
ISA
100
134
preserve
100-110
100-110
T7
Amlodipine
OrganicChemical
100
110
preserve
116-134
124-134
T8
calcium antagonist
PharmacologicSubstance
116
134
A5
Amlodipine is a calcium antagonist with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the treatment of hypertension.
100-250
100
250
@SUBJECT$ @PREDICAT$ @OBJECT$ with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the treatment of hypertension.
Fact
preserve
100-134
124-134
T16
Amlodipine is a calcium antagonist
TREATS
100
134
preserve
100-110
100-110
T7
Amlodipine
OrganicChemical
100
110
preserve
237-249
237-249
T13
hypertension
DiseaseOrSyndrome
237
249
A6
Amlodipine is a calcium antagonist with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the treatment of hypertension.
100-250
100
250
@SUBJECT$ @PREDICAT$ with a long elimination half-life (35 to 50 h) allowing a once daily dosing in the treatment of @OBJECT$ .
Uncommitted
preserve
419-421
419-421
T31
in
TREATS
419
421
preserve
411-418
411-418
T24
therapy
TherapeuticOrPreventiveProcedure
411
418
preserve
485-493
485-493
T29
patients
PatientOrDisabledGroup
485
493
A7
3 days after discontinuing therapy in previously well-controlled mild to moderate hypertensive patients.
384-494
384
494
3 days after discontinuing @SUBJECT$ @PREDICAT$ previously well-controlled mild to moderate hypertensive @OBJECT$ .
Fact
preserve
1635-1659
1650-1659
T90
cyclooxygenase enzymatic
ASSOCIATED_WITH
1,635
1,659
preserve
1635-1649
1635-1649
T77
cyclooxygenase
AminoAcidPeptideOrProtein
1,635
1,649
preserve
1690-1702
1690-1702
T81
hypertension
DiseaseOrSyndrome
1,690
1,702
A1
CONCLUSIONS: Nonselective inhibition of the cyclooxygenase enzymatic system does not influence the hypertension seen in the rat preeclampsia model induced by chronic nitric oxide deficiency.
1585-1787
1,585
1,787
CONCLUSIONS: Nonselective inhibition of the @SUBJECT$ @PREDICAT$ system does not influence the @OBJECT$ seen in the rat preeclampsia model induced by chronic nitric oxide deficiency.
Probable
preserve
1842-1850
1842-1850
T95
reversed
TREATS
1,842
1,850
preserve
1856-1868
1856-1868
T93
prostacyclin
BiologicallyActiveSubstance
1,856
1,868
preserve
1798-1810
1798-1810
T91
hypertension
DiseaseOrSyndrome
1,798
1,810
A2
The hypertension in this model can be partially reversed with prostacyclin analogs.
1788-1877
1,788
1,877
The @OBJECT$ in this model can be partially @PREDICAT$ with @SUBJECT$ analogs.
Fact
preserve
1346-1353
1346-1353
T69
induced
CAUSES
1,346
1,353
preserve
1378-1399
1394-1399
T67
arginine methyl ester
AminoAcidPeptideOrProtein
1,378
1,399
preserve
1333-1345
1333-1345
T66
hypertension
DiseaseOrSyndrome
1,333
1,345
A3
RESULTS: Except for an increase on the day after insertion of the pump indomethacin had no significant effect on the hypertension induced by N G -nitro- L -arginine methyl ester.
1210-1400
1,210
1,400
RESULTS: Except for an increase on the day after insertion of the pump indomethacin had no significant effect on the @OBJECT$ @PREDICAT$ by N G -nitro- L - @SUBJECT$ .
Fact
preserve
1635-1659
1650-1659
T88
cyclooxygenase enzymatic
ISA
1,635
1,659
preserve
1635-1649
1635-1649
T77
cyclooxygenase
AminoAcidPeptideOrProtein
1,635
1,649
preserve
1650-1659
1650-1659
T78
enzymatic
Enzyme
1,650
1,659
A5
CONCLUSIONS: Nonselective inhibition of the cyclooxygenase enzymatic system does not influence the hypertension seen in the rat preeclampsia model induced by chronic nitric oxide deficiency.
1585-1787
1,585
1,787
CONCLUSIONS: Nonselective inhibition of the @SUBJECT$ @PREDICAT$ @OBJECT$ system does not influence the hypertension seen in the rat preeclampsia model induced by chronic nitric oxide deficiency.
Counterfact
preserve
1319-1325
1319-1325
T68
effect
AFFECTS
1,319
1,325
preserve
1287-1299
1287-1299
T63
indomethacin
OrganicChemical
1,287
1,299
preserve
1333-1345
1333-1345
T66
hypertension
DiseaseOrSyndrome
1,333
1,345
A8
RESULTS: Except for an increase on the day after insertion of the pump indomethacin had no significant effect on the hypertension induced by N G -nitro- L -arginine methyl ester.
1210-1400
1,210
1,400
RESULTS: Except for an increase on the day after insertion of the pump @SUBJECT$ had no significant @PREDICAT$ on the @OBJECT$ induced by N G -nitro- L -arginine methyl ester.
Fact
preserve
1489-1491
1489-1491
T76
in
TREATS
1,489
1,491
preserve
1419-1427
1419-1427
T71
agonists
PharmacologicSubstance
1,419
1,427
preserve
1492-1506
1498-1506
T74
blood pressure
Finding
1,492
1,506
A9
Both prostacyclin agonists (iloprost and cicaprost), however, attenuated the rise in blood pressure usually seen after N G -nitro- L -arginine methyl ester administration.
1401-1584
1,401
1,584
Both prostacyclin @SUBJECT$ (iloprost and cicaprost), however, attenuated the rise @PREDICAT$ @OBJECT$ usually seen after N G -nitro- L -arginine methyl ester administration.
Fact
preserve
2202-2222
2214-2222
T147
obese patients
PROCESS_OF
2,202
2,222
preserve
2202-2207
2202-2207
T135
obese
DiseaseOrSyndrome
2,202
2,207
preserve
2214-2222
2214-2222
T136
patients
PatientOrDisabledGroup
2,214
2,222
A2
Concerning the influence of metabolic and nutritional factors, an impaired somatotropin response to hypoglycaemia and a failure of glucose load to inhibit spontaneous and stimulated GH release are well documented in obese patients; furthermore, drugs able to block lipolysis and thus to lower serum free fatty acids (NEFA) significantly improve somatotropin secretion in obesity.
1973-2377
1,973
2,377
Concerning the influence of metabolic and nutritional factors, an impaired somatotropin response to hypoglycaemia and a failure of glucose load to inhibit spontaneous and stimulated GH release are well documented in @SUBJECT$ @PREDICAT$ @OBJECT$ ; furthermore, drugs able to block lipolysis and thus to lower serum free fatty acids (NEFA) significantly improve somatotropin secretion in obesity.
Fact
preserve
1612-1614
1612-1614
T96
in
ASSOCIATED_WITH
1,612
1,614
preserve
1519-1526
1519-1526
T89
IGFBP-3
AminoAcidPeptideOrProtein
1,519
1,526
preserve
1621-1628
1621-1628
T95
obesity
DiseaseOrSyndrome
1,621
1,628
A3
As for the peripheral limb of the GH-insulin-like growth factor I (IGF-I) axis, high free IGF-I, low IGF-binding proteins 1 (IGFBP-1) and 2 (IGFBP-2), normal or high IGFBP-3 and increased GH binding protein (GHBP) circulating levels have been described in obesity.
1340-1629
1,340
1,629
As for the peripheral limb of the GH-insulin-like growth factor I (IGF-I) axis, high free IGF-I, low IGF-binding proteins 1 (IGFBP-1) and 2 (IGFBP-2), normal or high @SUBJECT$ and increased GH binding protein (GHBP) circulating levels have been described @PREDICAT$ @OBJECT$ .
Fact
preserve
900-902
900-902
T52
in
ASSOCIATED_WITH
900
902
preserve
895-899
895-899
T50
GHRH
AminoAcidPeptideOrProtein
895
899
preserve
903-910
903-910
T51
obesity
DiseaseOrSyndrome
903
910
A6
Compounds thought to inhibit hypothalamic somatostatin (SRIH) release (pyridostigmine, arginine, galanin, atenolol) consistently improve, though do not normalize, the somatotropin response to GHRH in obesity.
685-911
685
911
Compounds thought to inhibit hypothalamic somatostatin (SRIH) release (pyridostigmine, arginine, galanin, atenolol) consistently improve, though do not normalize, the somatotropin response to @SUBJECT$ @PREDICAT$ @OBJECT$ .
Fact
preserve
3195-3199
3195-3199
T201
with
USES
3,195
3,199
preserve
3185-3194
3185-3194
T191
treatment
TherapeuticOrPreventiveProcedure
3,185
3,194
preserve
3213-3215
3213-3215
T192
GH
AminoAcidPeptideOrProtein
3,213
3,215
A8
In spite of this, treatment with biosynthetic GH has been shown to improve the body composition and the metabolic efficacy of lean body mass in obese patients undergoing therapeutic severe caloric restriction.
3167-3388
3,167
3,388
In spite of this, @SUBJECT$ @PREDICAT$ biosynthetic @OBJECT$ has been shown to improve the body composition and the metabolic efficacy of lean body mass in obese patients undergoing therapeutic severe caloric restriction.
Fact
preserve
1612-1614
1612-1614
T96
in
ASSOCIATED_WITH
1,612
1,614
preserve
1547-1565
1558-1565
T91
GH binding protein
AminoAcidPeptideOrProtein
1,547
1,565
preserve
1621-1628
1621-1628
T95
obesity
DiseaseOrSyndrome
1,621
1,628
A9
As for the peripheral limb of the GH-insulin-like growth factor I (IGF-I) axis, high free IGF-I, low IGF-binding proteins 1 (IGFBP-1) and 2 (IGFBP-2), normal or high IGFBP-3 and increased GH binding protein (GHBP) circulating levels have been described in obesity.
1340-1629
1,340
1,629
As for the peripheral limb of the GH-insulin-like growth factor I (IGF-I) axis, high free IGF-I, low IGF-binding proteins 1 (IGFBP-1) and 2 (IGFBP-2), normal or high IGFBP-3 and increased @SUBJECT$ (GHBP) circulating levels have been described @PREDICAT$ @OBJECT$ .
Fact
preserve
157-171
163-171
T22
obese patients
PROCESS_OF
157
171
preserve
157-162
157-162
T9
obese
DiseaseOrSyndrome
157
162
preserve
163-171
163-171
T10
patients
PatientOrDisabledGroup
163
171
A11
In fact obese patients display, compared to normal weight subjects, a reduced half-life, frequency of secretory episodes and daily production rate of the hormone.
149-323
149
323
In fact @SUBJECT$ @PREDICAT$ @OBJECT$ display, compared to normal weight subjects, a reduced half-life, frequency of secretory episodes and daily production rate of the hormone.
Possible
preserve
3456-3463
3456-3463
T208
therapy
TREATS
3,456
3,463
preserve
3389-3391
3389-3391
T203
GH
AminoAcidPeptideOrProtein
3,389
3,391
preserve
3467-3474
3467-3474
T207
obesity
DiseaseOrSyndrome
3,467
3,474
A12
GH and conceivably GHRPs might therefore have a place in the therapy of obesity.
3389-3475
3,389
3,475
@SUBJECT$ and conceivably GHRPs might therefore have a place in the @PREDICAT$ of @OBJECT$ .
Uncommitted
preserve
15-17
15-17
T3
in
ASSOCIATED_WITH
15
17
preserve
0-14
7-14
T1
Growth hormone
AminoAcidPeptideOrProtein
0
14
preserve
18-25
18-25
T2
obesity
DiseaseOrSyndrome
18
25
A15
Growth hormone in obesity.
0-26
0
26
@SUBJECT$ @PREDICAT$ @OBJECT$ .
Fact
preserve
346-373
364-373
T39
patients GH secretion
PROCESS_OF
346
373
preserve
355-373
364-373
T24
GH secretion
CellFunction
355
373
preserve
346-354
346-354
T23
patients
PatientOrDisabledGroup
346
354
A16
Furthermore, in these patients GH secretion is impaired in response to all traditional pharmacological stimuli acting at the hypothalamus (insulin-induced hypoglycaemia, arginine, galanin, L-dopa, clonidine, acute glucocorticoid administration) and to direct somatotrope stimulation by exogenous growth hormone releasing hormone (GHRH).
324-684
324
684
Furthermore, in these @OBJECT$ @PREDICAT$ @SUBJECT$ is impaired in response to all traditional pharmacological stimuli acting at the hypothalamus (insulin-induced hypoglycaemia, arginine, galanin, L-dopa, clonidine, acute glucocorticoid administration) and to direct somatotrope stimulation by exogenous growth hormone releasing hormone (GHRH).
Fact
preserve
1870-1889
1882-1889
T121
human obesity
PROCESS_OF
1,870
1,889
preserve
1882-1889
1882-1889
T115
obesity
DiseaseOrSyndrome
1,882
1,889
preserve
1870-1875
1870-1875
T114
human
Human
1,870
1,875
A17
Recent evidence suggests that leptin, the product of adipocyte specific ob gene, exerts a stimulating effect on GH release in rodents; should the same hold true in man, the coexistence of high leptin and low GH serum levels in human obesity would fit in well with the concept of a leptin resistance in this condition.
1630-1972
1,630
1,972
Recent evidence suggests that leptin, the product of adipocyte specific ob gene, exerts a stimulating effect on GH release in rodents; should the same hold true in man, the coexistence of high leptin and low GH serum levels in @OBJECT$ @PREDICAT$ @SUBJECT$ would fit in well with the concept of a leptin resistance in this condition.
Fact
preserve
3323-3337
3329-3337
T202
obese patients
PROCESS_OF
3,323
3,337
preserve
3323-3328
3323-3328
T196
obese
DiseaseOrSyndrome
3,323
3,328
preserve
3329-3337
3329-3337
T197
patients
PatientOrDisabledGroup
3,329
3,337
A19
In spite of this, treatment with biosynthetic GH has been shown to improve the body composition and the metabolic efficacy of lean body mass in obese patients undergoing therapeutic severe caloric restriction.
3167-3388
3,167
3,388
In spite of this, treatment with biosynthetic GH has been shown to improve the body composition and the metabolic efficacy of lean body mass in @SUBJECT$ @PREDICAT$ @OBJECT$ undergoing therapeutic severe caloric restriction.
Fact
preserve
2366-2368
2366-2368
T150
in
ASSOCIATED_WITH
2,366
2,368
preserve
2343-2355
2343-2355
T143
somatotropin
AminoAcidPeptideOrProtein
2,343
2,355
preserve
2369-2376
2369-2376
T145
obesity
DiseaseOrSyndrome
2,369
2,376
A20
Concerning the influence of metabolic and nutritional factors, an impaired somatotropin response to hypoglycaemia and a failure of glucose load to inhibit spontaneous and stimulated GH release are well documented in obese patients; furthermore, drugs able to block lipolysis and thus to lower serum free fatty acids (NEFA) significantly improve somatotropin secretion in obesity.
1973-2377
1,973
2,377
Concerning the influence of metabolic and nutritional factors, an impaired somatotropin response to hypoglycaemia and a failure of glucose load to inhibit spontaneous and stimulated GH release are well documented in obese patients; furthermore, drugs able to block lipolysis and thus to lower serum free fatty acids (NEFA) significantly improve @SUBJECT$ secretion @PREDICAT$ @OBJECT$ .
Fact
preserve
2196-2209
2202-2209
T146
obese patient
PROCESS_OF
2,196
2,209
preserve
2196-2201
2196-2201
T132
obese
DiseaseOrSyndrome
2,196
2,201
preserve
2202-2209
2202-2209
T133
patient
PatientOrDisabledGroup
2,202
2,209
A2
Our data suggest that laparoscopic renal and adrenal surgery is technically feasible in the markedly and morbidly obese patient, and compared with open surgery results in significantly decreased blood loss, quicker return of bowel function, less analgesic requirement, shorter convalescence and reduced hospital stay.
2075-2417
2,075
2,417
Our data suggest that laparoscopic renal and adrenal surgery is technically feasible in the markedly and morbidly @SUBJECT$ @PREDICAT$ @OBJECT$ , and compared with open surgery results in significantly decreased blood loss, quicker return of bowel function, less analgesic requirement, shorter convalescence and reduced hospital stay.
Fact
preserve
1046-1074
1066-1074
T76
inferior vena caval thrombus
LOCATION_OF
1,046
1,074
preserve
1046-1065
1060-1065
T71
inferior vena caval
BodyLocationOrRegion
1,046
1,065
preserve
1066-1074
1066-1074
T72
thrombus
DiseaseOrSyndrome
1,066
1,074
A4
Open group patients with factors precluding laparoscopic surgery were excluded from the study (mass greater than 10 cm., renal vein and/or inferior vena caval thrombus and extension outside Gerota's fascia).
895-1120
895
1,120
Open group patients with factors precluding laparoscopic surgery were excluded from the study (mass greater than 10 cm., renal vein and/or @SUBJECT$ @PREDICAT$ @OBJECT$ and extension outside Gerota's fascia).
Fact
preserve
1972-1986
1978-1986
T125
obese patients
PROCESS_OF
1,972
1,986
preserve
1972-1977
1972-1977
T118
obese
DiseaseOrSyndrome
1,972
1,977
preserve
1978-1986
1978-1986
T119
patients
PatientOrDisabledGroup
1,978
1,986
A5
CONCLUSIONS: Markedly obese patients have an increased risk of complications from surgery, regardless of the approach.
1944-2074
1,944
2,074
CONCLUSIONS: Markedly @SUBJECT$ @PREDICAT$ @OBJECT$ have an increased risk of complications from surgery, regardless of the approach.
Fact
preserve
210-224
216-224
T20
obese patients
PROCESS_OF
210
224
preserve
210-215
210-215
T17
obese
DiseaseOrSyndrome
210
215
preserve
216-224
216-224
T18
patients
PatientOrDisabledGroup
216
224
A6
PURPOSE: The efficacy and morbidity of laparoscopic renal and adrenal surgery in comparison to open surgery in obese patients are unknown.
92-237
92
237
PURPOSE: The efficacy and morbidity of laparoscopic renal and adrenal surgery in comparison to open surgery in @SUBJECT$ @PREDICAT$ @OBJECT$ are unknown.